Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc.

PLPL
Plandaí Biotechnology, Inc.US flagOther OTC
0.00
USD
- -
- -
448,895.00Market Cap
Plandaí Biotechnology, Inc.
PLPL
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2022
2023
TTM
FRC
1,804
2,660.57
404.87
452.06
401.4
333.67
1.13
0.79
0.63
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-277.46
-312.94
-61.25
-21.08
-30.83
-56.1
-0.18
-0.08
-0.05
-0.04
-0.02
-0.14
-0.08
-0.03
- -
- -
-0.02
Basic EPS, GAAP
-122.29
-122.29
-60.81
-22.49
-79.95
-13.18
0.05
-0.04
0.03
-0.07
-0.03
-0.03
-0.03
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-588.4
-588.4
-131.59
-136.18
-152.32
-199.62
-1.43
-0.83
-0.84
-0.09
-0.1
-0.23
-0.32
-0.23
-0.01
-0.01
-0.16
Book Value per Share
-294.33
-294.33
-84.67
-79.43
-31.15
-89.85
-0.65
-0.42
-0.45
-0.01
-0.03
-0.04
-0.07
-0.07
- -
- -
-0.05
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
6
11
11
96
111
115
115
174
6,366
7,548
263
Basic Weighted Avg Shares
5
8
10
13
13
11
6
9
7
- -
- -
- -
- -
- -
- -
- -
1
Sales/Revenue/Turnover
-15.13
-12.27
-15.72
-4.21
-6.84
-3.32
-11.28
-8.07
-6.76
-5,117.09
-740.03
-1,785.27
-9,526.11
-1,041.5
- -
- -
-611.37
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
1
Depreciation Expense
-1
-1
-2
-1
-1
-2
-1
-1
-1
-4
-2
-16
-10
-4
7
-20
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-15.38
-11.76
-15.13
-4.66
-7.68
-16.81
-16.33
-9.71
-7.65
-5,073.3
-609.23
-5,873.14
-10,315.03
-1,467.07
- -
- -
-882.83
Profit Margin (%)
-1
-1
-2
-2
1
-1
-4
-5
-5
- -
- -
-3
-15
-17
-2
- -
-18
Working Capital
- -
- -
1
1
2
- -
- -
- -
- -
6
11
9
- -
- -
- -
- -
- -
LT Debt
-1
-1
-2
-2
-1
-3
-4
-5
-5
-1
-3
-4
-8
-12
-2
- -
-14
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-20.42
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'22
Dec'22
Mar'22
ST Debt
15
16
17
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
244
260
315
Market Capitalization
3
6
5

Working Capital

FRC

in mil. unless spec.
Sep'22
Dec'22
Mar'22
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
18
18
19
Payables & Accruals
2
2
2
ST Debt
15
16
17
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.5%
1.32%
-71%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
32.25%
-25.12%
-390.16%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Business
Plandaí Biotechnology, Inc. (PLPL) focuses on the production of proprietary botanical extracts for the nutraceutical and pharmaceutical industries; it develops and commercializes Phytofare Catechin Complex, a green tea-derived extract harvested from its Senteeko Tea Estate in Mpumalanga, South Africa, along with Phytofare citrus complex from citrus fruits, lycopene from tomatoes, extracts from Artemisia and cannabis, citrus bioflavonoids, limonoids, and Pheroid technology for entrapped delivery of these extracts; the company also produces and sells timber and agricultural products from its South African farm and tea estate holdings. Incorporated in Nevada in 2004 and headquartered in London, United Kingdom, with principal operations in South Africa under a 50-year lease on a 3,000-hectare estate, Plandaí Biotechnology serves global markets in health, wellness, and pharmaceutical sectors through its subsidiaries. In 2023, the company entered into a share exchange agreement to acquire Good Salt, LLC, incorporating assets of ByoPlanet International and Clean Republic for electrostatic disinfection technology focused on health innovation in animal health, commercial cleaning, and public services, with plans to rebrand as ByoPlanet, Inc., though the agreement was later rescinded due to failure of consideration; it completed audits for fiscal years 2021 and 2022 in preparation for potential uplisting.